292 related articles for article (PubMed ID: 24109221)
21. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
[TBL] [Abstract][Full Text] [Related]
22. Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.
Wang S; Parker C; Taaffe J; Solórzano A; García-Sastre A; Lu S
Vaccine; 2008 Jul; 26(29-30):3626-33. PubMed ID: 18538900
[TBL] [Abstract][Full Text] [Related]
23. Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes.
Park BR; Subbiah J; Kim KH; Kwon YM; Oh J; Kim MC; Shin CH; Seong BL; Kang SM
Virology; 2022 Jan; 566():143-152. PubMed ID: 34929590
[TBL] [Abstract][Full Text] [Related]
24. Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination.
Islam S; Mohn KG; Krammer F; Sanne M; Bredholt G; Jul-Larsen Å; Tete SM; Zhou F; Brokstad KA; Cox RJ
Vaccine; 2017 Oct; 35(42):5666-5673. PubMed ID: 28899626
[TBL] [Abstract][Full Text] [Related]
25. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.
Wei CJ; Boyington JC; McTamney PM; Kong WP; Pearce MB; Xu L; Andersen H; Rao S; Tumpey TM; Yang ZY; Nabel GJ
Science; 2010 Aug; 329(5995):1060-4. PubMed ID: 20647428
[TBL] [Abstract][Full Text] [Related]
26. Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans.
Khurana S; Hahn M; Coyle EM; King LR; Lin TL; Treanor J; Sant A; Golding H
Nat Commun; 2019 Jul; 10(1):3338. PubMed ID: 31350391
[TBL] [Abstract][Full Text] [Related]
27. Identification of H7N9 hemagglutinin novel protein epitopes that elicit strong antibody-dependent, cell-mediated cytotoxic activities with protection from influenza infection in mouse model.
Zhu P; Yi X; Zhang L; Liu Y; Wang S; Gu J; Zhu X; Yu X
Cell Immunol; 2021 Jan; 359():104255. PubMed ID: 33316647
[TBL] [Abstract][Full Text] [Related]
28. Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months-9 years: a prospective study.
McVernon J; Laurie K; Barr I; Kelso A; Skeljo M; Nolan T
Influenza Other Respir Viruses; 2011 Jan; 5(1):7-11. PubMed ID: 21138535
[TBL] [Abstract][Full Text] [Related]
29. Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains.
Wang J; Li D; Perry S; Hilchey SP; Wiltse A; Treanor JJ; Sangster MY; Zand MS
mBio; 2021 Aug; 12(4):e0044921. PubMed ID: 34225490
[TBL] [Abstract][Full Text] [Related]
30. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes.
Pushko P; Pearce MB; Ahmad A; Tretyakova I; Smith G; Belser JA; Tumpey TM
Vaccine; 2011 Aug; 29(35):5911-8. PubMed ID: 21723354
[TBL] [Abstract][Full Text] [Related]
31. Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance.
Skowronski DM; Hamelin ME; Janjua NZ; De Serres G; Gardy JL; Rhéaume C; Bouhy X; Boivin G
PLoS One; 2012; 7(6):e38929. PubMed ID: 22745690
[TBL] [Abstract][Full Text] [Related]
32. Development of a Pan-H1 Influenza Vaccine.
Darricarrère N; Pougatcheva S; Duan X; Rudicell RS; Chou TH; DiNapoli J; Ross TM; Alefantis T; Vogel TU; Kleanthous H; Wei CJ; Nabel GJ
J Virol; 2018 Nov; 92(22):. PubMed ID: 30185594
[TBL] [Abstract][Full Text] [Related]
33. Divergent H7 immunogens offer protection from H7N9 virus challenge.
Krammer F; Albrecht RA; Tan GS; Margine I; Hai R; Schmolke M; Runstadler J; Andrews SF; Wilson PC; Cox RJ; Treanor JJ; García-Sastre A; Palese P
J Virol; 2014 Apr; 88(8):3976-85. PubMed ID: 24453375
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
Frenck RW; Belshe R; Brady RC; Winokur PL; Campbell JD; Treanor J; Hay CM; Dekker CL; Walter EB; Cate TR; Edwards KM; Hill H; Wolff M; Leduc T; Tornieporth N
Vaccine; 2011 Aug; 29(34):5666-74. PubMed ID: 21699951
[TBL] [Abstract][Full Text] [Related]
35. Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses.
Allen JD; Ray S; Ross TM
PLoS One; 2018; 13(9):e0204284. PubMed ID: 30265682
[TBL] [Abstract][Full Text] [Related]
36. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
[TBL] [Abstract][Full Text] [Related]
37. Modified vaccinia virus Ankara expressing the hemagglutinin of pandemic (H1N1) 2009 virus induces cross-protective immunity against Eurasian 'avian-like' H1N1 swine viruses in mice.
Castrucci MR; Facchini M; Di Mario G; Garulli B; Sciaraffia E; Meola M; Fabiani C; De Marco MA; Cordioli P; Siccardi A; Kawaoka Y; Donatelli I
Influenza Other Respir Viruses; 2014 May; 8(3):367-75. PubMed ID: 24373385
[TBL] [Abstract][Full Text] [Related]
38. Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.
Broecker F; Zheng A; Suntronwong N; Sun W; Bailey MJ; Krammer F; Palese P
J Virol; 2019 Sep; 93(18):. PubMed ID: 31375573
[TBL] [Abstract][Full Text] [Related]
39. Antibody-dependent cell-mediated cytotoxicity antibody responses to inactivated and live-attenuated influenza vaccination in children during 2014-15.
Florek K; Mutschler J; McLean HQ; King JP; Flannery B; Belongia EA; Friedrich TC
Vaccine; 2020 Feb; 38(8):2088-2094. PubMed ID: 31753674
[TBL] [Abstract][Full Text] [Related]
40. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
J Virol; 2017 May; 91(9):. PubMed ID: 28179535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
